zantrene

0:06:42

Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®

0:02:45

Race Oncology welcomes positive pre-IND meeting for Zantrene

0:00:36

Race trials new Zantrene drug for Extramedullary Acute Myeloid Leukaemia (EMD AML) – Animation

0:07:33

Race Oncology fields promising early results from Zantrene kidney cancer program

0:05:00

Race Oncology secures governance approval for open-label Zantrene trial

0:20:31

Race Oncology (ASX: RAC) – Zantrene’s Role As An FTO Inhibitor To Cure Cancer Globally

0:05:40

Race Oncology Ltd advances Zantrene AML trials

0:06:42

Race Oncology looks to accelerate clinical development of bisantrene

0:04:59

Interview with Dr Ron Hargreaves - 'The Early Development of Bisantrene'

0:08:00

Race Oncology highlights impressive bisantrene clinical data

0:00:49

Race Oncology reports Bisantrene shows potent anti-cancer activity

0:08:20

Race Oncology at the heart of cancer care

0:11:26

Race Oncology's Daniel Tillett details positive preclinical results for Bisantrene in breast cancer

0:05:15

Race Oncology completes GLP studies for RC220 bisantrene; closer to human trials

0:39:10

Triangle Insights presents insights from their commercial assessment of Zantrene

0:01:13

Bisantrene for R/R AML patients

0:10:59

Interview with Dr Ving Lee - 'The Early Development of Bisantrene'

0:01:20

Daniel Tillett on Race Oncology's drug advancements

0:03:39

Executive interview - Race Oncology

0:06:49

Race Oncology receives positive results from AML trial of Bisantrene

0:27:43

Race presents at IRD Invest

0:06:43

Race Oncology’s RC220 trial gets green light

0:00:47

Race Oncology Bisantrene Production

0:08:05

Race Oncology receives US FDA rare paediatric disease designation for AML treatment